Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547625 · ClinicalTrials.gov registry record · Phase 2
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
A Phase 2 study of Prostatic Hyperplasia and Prostate, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
- 1
- Study location
NCT00547625: Completed Phase 2 study of Prostatic Hyperplasia and Prostate, sponsored by Eli Lilly and Company.
NCT00547625 is a Phase 2 study of Prostatic Hyperplasia and Prostate that has completed, run by Eli Lilly and Company. The registered enrollment target is 275 participants, below the 3,006-participant average among 5 other Prostatic Hyperplasia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547625, a Phase 2 study of Prostatic Hyperplasia and Prostate, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tadalafil
Study Locations (1)
Illinois
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00547625 record still lists
NCT00547625 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, below the 3,006-participant average among 5 other Prostatic Hyperplasia trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00547625 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00547625 about?
NCT00547625 is a clinical study titled "Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems". Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
What is the current status of trial NCT00547625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2004-10. Estimated completion is 2005-07.
What conditions does trial NCT00547625 study?
This clinical trial studies the following conditions: Prostatic Hyperplasia, Prostate.
What interventions are being tested in trial NCT00547625?
The interventions under investigation include: placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00547625?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00547625 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
RECRUITING · Phase 2
-
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
RECRUITING
-
Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
ACTIVE NOT RECRUITING · NA
-
Prostate Mechanical Imager (PMI) Clinical Bridging Study
COMPLETED
-
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia